Fludarabine modulates composition and function of the T cell pool in patients with chronic lymphocytic leukaemia

Cancer Immunology, Immunotherapy

Volumn 60, Issue 1, 2011, Pages 75-85

  Gassner, Franz Josef ^a   Weiss, Lukas ^a   Geisberger, Roland ^a   Hofbauer, Josefina Piñón ^a   Egle, Alexander ^a   Hartmann, Tanja Nicole ^a   Greil, Richard ^a   Tinhofer, Inge ^a,b  

^a PARACELSUS MEDICAL UNIVERSITY   (Austria)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

CLL; Fludarabine; Immunomodulation; T cells

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; CYCLOPHOSPHAMIDE; CYTOKINE; FLUDARABINE; MAFOSFAMIDE;

ADULT; AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL COMPOSITION; CELL SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG EFFICACY; DRUG MECHANISM; FEMALE; HUMAN; HUMAN CELL; LEUKEMIA CELL; LYMPHOCYTE FUNCTION; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; T CELL DEPLETION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; ANTIGENS, CD; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; FEMALE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; MYELOABLATIVE AGONISTS; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES; VIDARABINE;

EID: 79953755051     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-010-0920-3     Document Type: Article

References (43)

1. Finn OJ (2008) Cancer immunology. N Engl J Med 358:2704-2715
2. Tam CS, Keating MJ (2007) Chemoimmunotherapy of chronic lymphocytic leukemia. Best Pract Res Clin Haematol 20:479-498 (Pubitemid 47263407)
3. Lake RA, Robinson BW (2005) Immunotherapy and chemotherapy - a practical partnership. Nat Rev Cancer 5:397-405 (Pubitemid 40637831)
4. Zitvogel L, Apetoh L, Ghiringhelli F, Andre F, Tesniere A, Kroemer G (2008) The anticancer immune response: indispensable for therapeutic success? J Clin Invest 118:1991-2001
5. Baxevanis CN, Perez SA, Papamichail M (2009) Combinatorial treatments including vaccines, chemotherapy and monoclonal antibodies for cancer therapy. Cancer Immunol Immunother 58:317-324
6. Dunussi-Joannopoulos K (2002) The combination of chemotherapy and systemic immunotherapy and the concept of cure in murine leukemia and lymphoma. Leuk Lymphoma 43:2075-2082
7. Frey AB, Monu N (2008) Signaling defects in anti-tumor T cells. Immunol Rev 222:192-205 (Pubitemid 351430368)
8. Tinhofer I, Marschitz I, Kos M, Henn T, Egle A, Villunger A, Greil R (1998) Difeerential sensitivity of CD4+ and CD8+ T lymphocytes to the killing efficacy of Fas (Apo-1/CD95) ligand+ tumor cells in B chronic lymphocytic leukemia. Blood 91:4273-4281 (Pubitemid 28261992)
9. Frydecka I, Kosmaczewska A, Bocko D, Ciszak L, Wolowiec D, Kuliczkowski K, Kochanowska I (2004) Alterations of the expression of T-cell-related costimulatory CD28 and downregulatory CD152 (CTLA-4) molecules in patients with B-cell chronic lymphocytic leukaemia. Br J Cancer 90:2042-2048 (Pubitemid 38746350)
10. Scrivener S, Goddard RV, Kaminski ER, Prentice AG (2003) Abnormal T-cell function in B-cell chronic lymphocytic leukaemia. Leuk Lymphoma 44:383-389 (Pubitemid 36118829)
11. Ramsay AG, Johnson AJ, Lee AM, Gorgun G, Le Dieu R, Blum W, Byrd JC, Gribben JG (2008) Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J Clin Invest 118:2427-2437 (Pubitemid 351949771)
12. Beyer M, Kochanek M, Darabi K, Popov A, Jensen M, Endl E, Knolle PA, Thomas RK, Bergwelt-Baildon M, Debey S, Hallek M, Schultze JL (2005) Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with Xudarabine. Blood 106:2018-2025 (Pubitemid 41291715)
13. Motta M, Rassenti L, Shelvin BJ, Lerner S, Kipps TJ, Keating MJ, Wierda WG (2005) Increased expression of CD152 (CTLA-4) by normal T lymphocytes in untreated patients with B-cell chronic lymphocytic leukemia. Leukemia 19:1788-1793 (Pubitemid 41486157)
14. Morrison VA (1998) The infectious complications of chronic lymphocytic leukemia. Semin Oncol 25:98-106
15. O'Brien S (1998) Clinical challenges in chronic lymphocytic leukemia. Semin Hematol 35:22-26
16. Hallek M, Schmitt B, Wilhelm M, Busch R, Krober A, Fostitsch HP, Sezer O, Herold M, Knauf W, Wendtner CM, Kuse R, Freund M, Franke A, Schriever F, Nerl C, Dohner H, Thiel E, Hiddemann W, Brittinger G, Emmerich B (2001) Fludarabine plus cyclophosphamide is an efficient treatment for advanced chronic lymphocytic leukaemia (CLL): results of a phase II study of the German CLL Study Group. Br J Haematol 114:342-348 (Pubitemid 32762233)
17. Schmitt B, Wendtner CM, Bergmann M, Busch R, Franke A, Pasold R, Schlag R, Hopfinger G, Hiddemann W, Emmerich B, Hallek M (2002) Fludarabine combination therapy for the treatment of chronic lymphocytic leukemia. Clin Lymphoma 3:26-35
18. Bosch F, Ferrer A, Lopez-Guillermo A, Gine E, Bellosillo B, Villamor N, Colomer D, Cobo F, Perales M, Esteve J, Altes A, Besalduch J, Ribera JM, Montserrat E (2002) Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia. Br J Haematol 119:976-984 (Pubitemid 35463822)
19. Keating MJ, O'Brien S, Albitar M, Lerner S, Plunkett W, Giles F, Andreeff M, Cortes J, Faderl S, Thomas D, Koller C, Wierda W, Detry MA, Lynn A, Kantarjian H (2005) Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 23:4079-4088 (Pubitemid 46211313)
20. Tsimberidou AM, Tam C, Abruzzo LV, O'Brien S, Wierda WG, Lerner S, Kantarjian HM, Keating MJ (2009) Chemoimmunotherapy may overcome the adverse prognostic significance of 11q deletion in previously untreated patients with chronic lymphocytic leukemia. Cancer 115:373-380
21. Foon KA, Boyiadzis M, Land SR, Marks S, Raptis A, Pietragallo L, Meisner D, Laman A, Sulecki M, Butchko A, Schaefer P, Lenzer D, Tarhini A (2009) Chemoimmunotherapy with low-dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol 27:498-503
22. Brode S, Cooke A (2008) Immune-potentiating effects of the chemotherapeutic drug cyclophosphamide. Crit Rev Immunol 28:109-126 (Pubitemid 351507425)
23. Robak T, Korycka A, Kasznicki M, Wrzesien-Kus A, Smolewski P (2005) Purine nucleoside analogues for the treatment of hematological malignancies: pharmacology and clinical applications. Curr Cancer Drug Targets 5:421-444 (Pubitemid 41178983)
24. Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS (1975) Clinical staging of chronic lymphocytic leukemia. Blood 46:219-234
25. Bichi R, Shinton SA, Martin ES, Koval A, Calin GA, Cesari R, Russo G, Hardy RR, Croce CM (2002) Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression. Proc Natl Acad Sci USA 99:6955-6960 (Pubitemid 34526239)
26. Johnson AJ, Lucas DM, Muthusamy N, Smith LL, Edwards RB, De Lay MD, Croce CM, Grever MR, Byrd JC (2006) Characterization of the TCL-1 transgenic mouse as a preclinical drug development tool for human chronic lymphocytic leukemia. Blood 108:1334-1338 (Pubitemid 44232033)
27. Holler C, Pinon JD, Denk U, Heyder C, Hofbauer S, Greil R, Egle A (2009) PKCbeta is essential for the development of chronic lymphocytic leukemia in the TCL1 transgenic mouse model: validation of PKCbeta as a therapeutic target in chronic lymphocytic leukemia. Blood 113:2791-2794
28. Bellosillo B, Villamor N, Colomer D, Pons G, Montserrat E, Gil J (1999) In vitro evaluation of fludarabine in combination with cyclophosphamide and/or mitoxantrone in B-cell chronic lymphocytic leukemia. Blood 94:2836-2843
29. McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME, Heyman MR, Bence-Bruckler I, White CA, Cabanillas F, Jain V, Ho AD, Lister J, Wey K, Shen D, Dallaire BK (1998) Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 16:2825-2833 (Pubitemid 28363048)
30. Dudley ME, Wunderlich JR, Yang JC, Sherry RM, Topalian SL, Restifo NP, Royal RE, Kammula U, White DE, Mavroukakis SA, Rogers LJ, Gracia GJ, Jones SA, Mangiameli DP, Pelletier MM, Gea-Banacloche J, Robinson MR, Berman DM, Filie AC, Abati A, Rosenberg SA (2005) Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 23:2346-2357 (Pubitemid 46218728)
31. Dudley ME, Yang JC, Sherry R, Hughes MS, Royal R, Kammula U, Robbins PF, Huang J, Citrin DE, Leitman SF, Wunderlich J, Restifo NP, Thomasian A, Downey SG, Smith FO, Klapper J, Morton K, Laurencot C, White DE, Rosenberg SA (2008) Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol 26:5233-5239
32. Pavon EJ, Munoz P, Navarro MD, Raya-Alvarez E, Callejas-Rubio JL, Navarro-Pelayo F, Ortego-Centeno N, Sancho J, Zubiaur M (2006) Increased association of CD38 with lipid rafts in T cells from patients with systemic lupus erythematosus and in activated normal T cells. Mol Immunol 43:1029-1039 (Pubitemid 41814420)
33. Savarino A, Bottarel F, Malavasi F, Dianzani U (2000) Role of CD38 in HIV-1 infection: an epiphenomenon of T-cell activation or an active player in virus/host interactions? AIDS 14:1079-1089
34. Boleslawski E, BenOthman S, Grabar S, Correia L, Podevin P, Chouzenoux S, Soubrane O, Calmus Y, Conti F (2008) CD25, CD28 and CD38 expression in peripheral blood lymphocytes as a tool to predict acute rejection after liver transplantation. Clin Transpl 22:494-501
35. Tinhofer I, Rubenzer G, Holler C, Hofstaetter E, Stoecher M, Egle A, Steurer M, Greil R (2006) Expression levels of CD38 in T cells predict course of disease in male patients with B-chronic lymphocytic leukemia. Blood 108:2950-2956
36. Abousamra NK, El Din MS, Azmy E (2009) T-cell CD38 expression in B-chronic lymphocytic leukaemia. Hematol Oncol 27:82-89
37. Koike N, Pilon-Thomas S, Mule JJ (2008) Nonmyeloablative chemotherapy followed by T-cell adoptive transfer and dendritic cell-based vaccination results in rejection of established melanoma. J Immunother 31:402-412 (Pubitemid 351595163)
38. Gladstone DE, Golightly MG, Brannagan TH III (2007) High dose cyclophosphamide preferentially targets naive T (CD45/CD4/RA+) cells in CIDP and MS patients. J Neuroimmunol 190:121-126 (Pubitemid 47625598)
39. Takada K, Danning CL, Kuroiwa T, Schlimgen R, Tassiulas IO, Davis JC Jr, Yarboro CH, Fleisher TA, Boumpas DT, Illei GG (2003) Lymphocyte depletion with fludarabine in patients with psoriatic arthritis: clinical and immunological effects. Ann Rheum Dis 62:1112-1115 (Pubitemid 37323578)
40. Gamberale R, Fernandez-Calotti P, Sanchez-Avalos J, Alberto MF, Geffner J, Giordano M (2006) The effect of fludarabine on interferon-gamma production by lymphoid cells from healthy donors and patients with B-cell chronic lymphocytic leukemia. Haematologica 91:574-576
41. Frank DA, Mahajan S, Ritz J (1999) Fludarabine-induced immunosuppression is associated with inhibition of STAT1 signaling. Nat Med 5:444-447 (Pubitemid 29180586)
42. Dearden C, Wade R, Else M, Richards S, Milligan D, Hamblin T, Catovsky D (2008) The prognostic significance of a positive direct antiglobulin test in chronic lymphocytic leukemia: a beneficial effect of the combination of fludarabine and cyclophosphamide on the incidence of hemolytic anemia. Blood 111:1820-1826 (Pubitemid 351451488)
43. Steurer M, Pall G, Richards S, Schwarzer G, Bohlius J, Greil R (2006) Purine antagonists for chronic lymphocytic leukaemia. Cochrane Database Syst Rev 3:CD004270